Inflammatory bowel diseases · 2026
Clinical Significance of Mucin Signatures in Inflammatory Bowel Diseases: A Systematic Review of Their Expression Patterns, Polymorphisms, and Post-translational Modifications.
СтатьяСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Arras Wout, Oosterlinck Baptiste, Gassman Julie, De Man Joris G, Jauregui-Amezaga Aranzazu, De Winter Benedicte Y, Smet Annemieke
Аннотация
BACKGROUND: The intestinal mucosal barrier plays an important role in the pathophysiology of inflammatory bowel disease (IBD), with mucins being key components of this barrier. Classified as either transmembrane or secreted, these highly glycosylated proteins protect the mucosal barrier while also influencing barrier integrity. Given their indispensable role in maintaining the intestinal mucosal barrier, mucins are compelling candidates for the evaluation of barrier dysfunction. Numerous studies have investigated mucins in the context of IBD, but a clear consensus regarding their expression, polymorphisms, and post-translational modifications is missing. This systematic review summarizes mucin alterations at the transcriptional, translational, and post-translational levels in the presence/absence of intestinal inflammation in IBD patients.
METHODS: To this end, PubMed, Scopus, and Web of Science were searched for studies published between February 1993 and January 2025, yielding 69 articles eligible for inclusion.
RESULTS: The expression of MUC1, MUC5AC, and MUC6 was reported to be upregulated at both RNA (isoform) and protein level, in contrast to MUC12, which exhibited reduced expression in inflamed mucosa only at RNA isoform level. MUC2 was the only mucin consistently downregulated at the protein level, despite unchanged mRNA expression, whereas polymorphisms of MUC2, MUC3A, MUC4, MUC13, MUC19, MUC21, and MUC22 were associated with susceptibility to Crohn's disease, ulcerative colitis, or IBD in general. Post-translational modifications, such as hypoglycosylation of MUC1 and MUC2, as well as a reduction of mucin sulphation of MUC2 were reported.
CONCLUSION: Together, these findings underscore the involvement of mucins in IBD and point to their potential as biomarkers for barrier dysfunction.
METHODS: To this end, PubMed, Scopus, and Web of Science were searched for studies published between February 1993 and January 2025, yielding 69 articles eligible for inclusion.
RESULTS: The expression of MUC1, MUC5AC, and MUC6 was reported to be upregulated at both RNA (isoform) and protein level, in contrast to MUC12, which exhibited reduced expression in inflamed mucosa only at RNA isoform level. MUC2 was the only mucin consistently downregulated at the protein level, despite unchanged mRNA expression, whereas polymorphisms of MUC2, MUC3A, MUC4, MUC13, MUC19, MUC21, and MUC22 were associated with susceptibility to Crohn's disease, ulcerative colitis, or IBD in general. Post-translational modifications, such as hypoglycosylation of MUC1 and MUC2, as well as a reduction of mucin sulphation of MUC2 were reported.
CONCLUSION: Together, these findings underscore the involvement of mucins in IBD and point to their potential as biomarkers for barrier dysfunction.